A recent study supports the potential of psilocybin, combined with psychological support, as an innovative treatment for major depressive disorder (MDD). This study, which spanned six weeks and was randomized and placebo-controlled, aimed to assess the safety and efficacy of a single psilocybin dose in 104 adult MDD patients aged 21 to 65. The participants received either a 25-mg dose of psilocybin or a placebo, with psychological support provided to all.
The study evaluated primary and secondary outcomes, as well as adverse events, at various intervals after dosing. The results showed that psilocybin treatment led to a significant reduction in Montgomery-Asberg Depression Rating Scale (MADRS) scores compared to niacin, both at day 8 and day 43 after baseline. Additionally, psilocybin treatment resulted in reduced Sheehan Disability Scale scores compared to niacin by day 43. The study concluded that psilocybin, when administered with psychological support, could offer a promising novel intervention for MDD without serious adverse effects.
